ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Upgraded by ValuEngine to Sell

ValuEngine upgraded shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) from a strong sell rating to a sell rating in a research report sent to investors on Tuesday, ValuEngine reports.

Separately, Jefferies Financial Group assumed coverage on shares of ASTELLAS PHARMA/ADR in a report on Tuesday, September 24th. They set a buy rating on the stock.

OTCMKTS ALPMY opened at $17.10 on Tuesday. The company has a fifty day simple moving average of $16.60 and a two-hundred day simple moving average of $14.62. The stock has a market cap of $31.83 billion, a P/E ratio of 16.44 and a beta of 0.78. ASTELLAS PHARMA/ADR has a 12-month low of $12.41 and a 12-month high of $17.33.

ASTELLAS PHARMA/ADR Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.

Featured Article: Why do commodities matter?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit